We are live on ! Find out more

Exagen

XGN

Market cap $211M

8.72 USD

-0.02

0.23%

At close Updated Sep 25, 4:00 PM EDT

Pre-market

After hours

8.60

-0.12

1.38%

1 day

-0.23%

5 days

1.51%

1 month

14.74%

3 months

87.93%

6 months

202.78%

Year to date

44.37%

1 year

-17.5%

5 years

-38.24%

10 years

-53.07%

About: Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.

Employees: 220

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 25%

Neutral 75%

Negative 0%

Exagen: The Path To Profitability Just Became More Credible

Exagen delivered a standout quarter, with 16% revenue growth, record ASP, and near-breakeven adjusted EBITDA, reinforcing the turnaround thesis. XGN raised full-year revenue guidance to $72-75M, with Pharma Services revenue tripling and backlog growing, highlighting new long-term growth levers. Operating margin improved to -8.6%, and Q2 cash generation turned positive, signaling tangible progress toward profitability and improved liquidity.

Exagen: The Path To Profitability Just Became More Credible

Exagen Q2 Earnings Call Highlights

Exagen NASDAQ: XGN reported record second-quarter revenue as growth in AVISE CTD test volume, average selling price and Pharma Services revenue brought the autoimmune diagnostics company close to adjusted EBITDA break-even.

Exagen Q2 Earnings Call Highlights

Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript

Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript

Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

Exagen Inc. (XGN) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.18 per share a year ago.

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

Exagen Inc. Reports Second Quarter 2026 Financial Results

Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million CARLSBAD, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2026, and recent corporate updates.

Exagen Inc. Reports Second Quarter 2026 Financial Results

Exagen Inc. to Participate in Upcoming Investor Conference

CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conference: Canaccord Genuity 46 th Annual Growth Conference – Boston, MA Date: August 11, 2026Fireside Chat at 8:30am ETA live and archived webcast of the Fireside Chat will be available on Exagen's Investor Relations website at investors.exagen.com.

Exagen Inc. to Participate in Upcoming Investor Conference

Exagen: A Small Diagnostics Company Approaching An Inflection Point

Exagen earns a Buy rating as revenue growth accelerates, ASPs improve, and break-even appears within reach despite ongoing cash burn. XGN leverages a growing proprietary autoimmune diagnostics database, positioning itself for long-term strategic value through AI-driven insights and biopharma partnerships. Gross margins remain stable near 60%, with breakeven targeted at $80M sales and 63% margins, achievable by 2027 if 10% annual growth continues.

Exagen: A Small Diagnostics Company Approaching An Inflection Point

Exagen to Announce Second Quarter Financial Results on August 4, 2026

CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026, before the market opens on Tuesday, August 4, 2026.

Exagen to Announce Second Quarter Financial Results on August 4, 2026

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive diagnosis Performed consistently across more than 1,200 SLE patients and 14 medical centers, expanding on the original clinical validation CARLSBAD, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the publication of a new systematic review demonstrating that the AVISE Lupus algorithm delivers markedly superior diagnostic accuracy and consistency across patient populations compared with conventional serologic tests alone.

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

Zacks Investment Research

How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%

The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in Exagen (XGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%

See News Rankings

Price charts implemented using Lightweight Charts™